GHRP-2 and GHRP-6 news and clinical trials

A narrative review of 76 studies on peptide use in urology and sexual medicine found that while some agents like Bremelanotide and Tesamorelin have clinical backing, many others like CJC-1295 remain unvalidated and accessible only through unregulated markets.

Researchers studied mice with hepatic Echinococcus granulosus infection and found that the GHSR antagonist [D-Lys3]-GHRP-6 effectively slowed disease progression by inhibiting liver cell proliferation and promoting beneficial fibrosis.

A study in HTR-8/SVneo cells found that ghrelin treatment at 1000 nmol/L protects trophoblasts against hypoxia-induced mitochondrial damage, oxidative stress, and apoptosis by downregulating TGFB2.

A study of 69 patients found that when the insulin tolerance test is contraindicated, clinicians can use the GHRP-2 stimulation test to help diagnose hypothalamic secondary adrenal insufficiency, where a peak cortisol level below 12 μg/dL is specific to this condition.

A case report describes a 62-year-old bodybuilder who developed dysphagia from anterior cervical osteophytes, raising the hypothesis that his 20-year history of exogenous growth hormone and GH secretagogue use may have contributed to significant bone growth.

A study in mice found that controlled ovarian hyperstimulation increases circulating ghrelin, which delays embryo development. Administration of ghrelin receptor antagonists like (D-Lys3)-GHRP-6 or PF-5190457 reversed this developmental delay.

New randomized trial in Journal of clinical neuroscience : official journal of the Neurosurgical…: Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke.

A review of peptides modulating the GH-IGF-1 axis highlights the significant gap between clinical evidence and unregulated self-administration protocols. Clinicians are advised to recognize potential adverse effects like endocrine disturbances, fluid retention, and metabolic issues.

Researchers established that the Ghrelin/GHSR-1a axis is compensatorily upregulated in preeclampsia and that exogenous ghrelin supplementation improves placental function and reduces preeclampsia-like symptoms in rats by reprogramming decidual macrophages.

Researchers found that GHRP-6 administration reduced myocardial fibrosis and scarring in rats with induced myocardial infarction. The treatment also improved left ventricle physiology by upregulating proteins involved in fatty acid oxidation and antioxidant defenses.

A study demonstrated that GHRP-6 administration attenuated lung damage and fibrosis in mice models of acute lung injury. GHRP-6 treatment reduced neutrophilic alveolitis and preserved lung parenchymal integrity by limiting collagen accumulation.

A study in common carp found that orally administered salmon acylated ghrelin increased feed intake without entering systemic circulation. The orexigenic effect occurred through local action on growth hormone secretagogue receptors and peripheral sensory neurons.

Researchers characterized GH secretion patterns in male cynomolgus monkeys and confirmed their responsiveness to exogenous GHRH. The study found that GHRH administration increased GH concentrations, supporting the use of this species for pituitary toxicity testing.

Researchers determined that ICV injection of LEAP-2 significantly decreased food intake in broiler chickens. The results suggest this hypophagic effect is mediated through ghrelin and CB1 and CB2 receptors.

Scientists designed a GHRP-6 peptide hydrogel that enhances recovery from acute kidney injury in mice. The treatment reprograms metabolism in renal tubular epithelial cells and activates the mTOR-P70 pathway to support cell survival.

Researchers synthesized aza-isotryptophan and incorporated it into GHRP-6 analogs to create modulators of the CD36 receptor. These analogs showed promising binding affinity and modulated inflammatory responses associated with the Toll-like receptor-2/6 heterodimer.